A scalpel for the microbiome
Microbiome science has spent a decade learning to read disease — identifying the specific strains whose presence tracks illness. Phages are the first tool precise enough to act on that reading: to remove a single keystone pathobiont from a community of thousands and ask whether the disease follows it out the door.
The premise
Reading is not enough — you need a way to edit
The central problem of translational microbiome medicine is the gap between correlation and causation. We can show that a strain is associated with a disease; proving it drives the disease requires removing it and watching what happens — without disturbing everything else. Antibiotics can’t do that; they erase the whole neighborhood. FMT moves the whole community at once. Only a phage can subtract one line item.
This is why phages and microbiome medicine are converging. The same disease-associated signatures catalogued by efforts like Microbiome Medicine become a target list for phage cocktails — and each successful, specific knockout simultaneously validates the intervention and the underlying signature.
Keystone pathobionts
Single strains, whole diseases
For a growing set of conditions, the literature now points at a specific organism. Each is a candidate for precision removal.
Klebsiella pneumoniae
IBD, PSC, liver inflammationA 5-phage cocktail suppressed an IBD-driving Kp clade with no off-target dysbiosis (Federici, Cell 2022) — the field’s cleanest proof of concept.
Cytolytic Enterococcus faecalis
Alcohol-associated hepatitisPhages targeting the cytolysin-producing strain abolished the toxin and attenuated liver disease in humanized mice (Duan, Nature 2019).
Fusobacterium nucleatum
Colorectal cancerDrug-conjugated phages selectively cleared intratumoral Fn and augmented chemotherapy (Nat Biomed Eng 2019).
Adherent-invasive E. coli
Crohn’s diseaseThe LF82-type strain; Intralytix’s EcoActive cocktail is in clinical trials in AIEC-colonized Crohn’s patients.
Klebsiella / Enterobacteriaceae
Necrotizing enterocolitisA pre-symptomatic bloom precedes NEC in preterm infants — the basis of this site’s flagship grant concept.
The phageome
We are already mostly phage
The healthy gut virome is overwhelmingly bacteriophage — dominated by crAss-like phages, highly individual to each person, and remarkably stable over time. In inflammatory bowel disease, that virome visibly expands and shifts in a disease-specific way. Phages aren’t foreign invaders we’re introducing; they’re a native regulatory layer of the microbiome we’re only beginning to operate deliberately.
Signature-locking
Holding a change in place
The hardest part of any microbiome intervention is durability — the displaced strain grows back. A phage cocktail is the natural maintenance layer: after a diet change, FMT, or realignment shifts the community, phages can suppress re-bloom of the unwanted strain and lock in the new signature. It is a precision instrument for the realignment process at the heart of microbiome medicine.
The through-line to the NICU flagship
Every thread here — keystone pathobionts, the preterm phageome, precision removal of Klebsiella — converges on a single, fundable first application.